Unlock instant, AI-driven research and patent intelligence for your innovation.

Peptide compounds used for treating diseases associated with hyperexcitability disorders and dysfunction of an ion channel

An overexcited, compound technology, applied in the screening of compounds, active ingredients of heterocyclic compounds, resistance to vector-borne diseases, etc.

Inactive Publication Date: 2014-01-08
UCB SA
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In practice, however, this does not strictly follow the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide compounds used for treating diseases associated with hyperexcitability disorders and dysfunction of an ion channel
  • Peptide compounds used for treating diseases associated with hyperexcitability disorders and dysfunction of an ion channel
  • Peptide compounds used for treating diseases associated with hyperexcitability disorders and dysfunction of an ion channel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0294] Initial studies showed that lacosamide alters the rapid inactivation of sodium channel gating in a manner inconsistent with the effects of existing antiepileptic agents. This is evidenced by the very limited effect of lacosamide on action potential initiation induced by brief depolarization steps or ramps. The lack of effect of lacosamide on rapid inactivation is further supported by experiments performed on Xenopus oocytes expressing only the alpha subunit of the sodium channel. Furthermore, lacosamide did not alter the rapid inactivation voltage profile or delay its recovery from steady-state rapid inactivation, as observed in neuroblastoma cells. In contrast to lacosamide having no effect, carbamazepine, lamotrigine and phenytoin all significantly altered these gating processes.

[0295] However, lacosamide still rapidly and profoundly inhibited sodium currents in a voltage-dependent manner in the oocyte expression system. Sodium channels in mouse neuroblastoma N1E...

Embodiment 2

[0314] Example 2: Lacosamide in a Stress-Induced Anxiety Animal Model

[0315] In the study the effects of lacosamide were tested in an animal model of stress-related anxiety. In this animal model, stress is induced by measuring rectal temperature. The stress-induced hyperthermia (SIH) test is based on the principle that mice have an innate hyperthermic response to stress that reflects levels of stress-induced anxiety. In this model, the effect of lacosamide was compared with that of the reference compound chlordiazepoxide (CDP), which is used clinically as a first-line anxiolytic treatment. In addition, the new anticonvulsant pregabalin, which was also developed for generalized anxiety disorders, was used as an additional reference compound.

[0316] Materials and methods

[0317] Adult male 129SVEV mice (8 weeks old) from Taconic Laboratories (Germantown, NY) were used in this study. Mice were housed in standard polycarbonate cages with filter tops. Four animals were ho...

Embodiment 3

[0326] The focus of this study was to analyze the potential neuroprotective effects of lacosamide in rat hippocampus slice cultures after exposure to glutamate (Glut) as a model of excitotoxic injury. Lacosamide was administered 2 hours before injury and until the end of the experiment 24 hours after injury. Quantification of necrotic cell death was performed by propidium iodide (PI) uptake (neuronal cell death in the CA1-CA3 region) and lactate dehydrogenase (LDH) release (cell death throughout the slice). Lacosamide shows protective effect against necrotic cell death after Glut. Due to the neuroprotective effects found in this study, lacosamide is speculated to be effective in the treatment of disorders associated with excitotoxic injury.

[0327] experimental method

[0328] Model system: organotypic hippocampal slice culture (OHC).

[0329] Organotypic slice cultures, where hippocampal slice cultures represent in vitro models that preserve distinct cell types and mainta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.

Description

[0001] This application is the branch of Chinese patent application 200780024517.2 (PCT / EP2007 / 005806), the filing date is June 29, 2007, and the title of the invention is "Peptide Compounds for the Treatment of Hyperexcitability Disorders and Diseases Related to Ion Channel Dysfunction" case application. technical field [0002] The present invention relates to the use of a class of peptide compounds for the treatment of diseases associated with hyperexcitability, such as diseases associated with hyperexcitable tissues. The present invention also relates to the use of a class of peptide compounds in the treatment of diseases associated with ion channel dysfunction. [0003] This application claims EP06021470.7 filed October 12, 2006, EP06021469.9 filed October 12, 2006, EP06013655.3 filed June 30, 2006, and EP06024241.9 filed November 22, 2006 priority, the disclosure of which is incorporated herein by reference. Background technique [0004] Certain polypeptides are know...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/165A61K31/341A61P21/00A61P25/28A61P25/08A61P29/00A61P25/04A61P27/16A61P13/12A61P25/22A61P25/18A61P25/00A61P25/02A61P25/16
CPCG01N2500/04G01N2800/2835C12N2503/02A61K31/165G01N33/6896G01N2800/302G01N2800/2857G01N2800/52G01N2800/2842A61K31/19A61K31/195A61K31/35A61K31/4015A61K31/4166A61K31/53A61K31/55A61K38/04A61K38/05A61K45/06A61P13/12A61P21/00A61P25/00A61P25/02A61P25/04A61P25/08A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/28A61P27/16A61P29/00A61P43/00A61P9/06Y02A50/30
Inventor C·希尔斯T·斯多尔B·拜罗伊特尔
Owner UCB SA